Immunoglobulins Sales Poised to Grow at 7.5% in 2021 as Neurology Application Deepens: Study
Global immunoglobulins sales are set to expand at nearly 7.5% in 2021, subsequent to a year of stagnancy in 2020. Demand surge can be highly ascribed to surge in prevalence of autoimmune ailments. The long-term prospects of immunoglobulins industry will increase as the worldwide geriatric population increases, so does the requirement for improved immunological treatments.
“Numerous key players have made huge investments in R&D programs for IMIG, SCIG and IVIG applications. Favorable results in new clinical applications are slated to generate lucrative prospects for the global immunoglobulins industry,” concludes a Fact.MR analyst. In the latest 2020-2030 edition of the study.
Request a report sample to gain comprehensive market insights at: https://www.factmr.com/connectus/sample?flag=S&rep_id=4788
How Treatment of Off-label Indications is Influencing Immunoglobulins Demand?
A steady increment in the use of immunoglobulins for the off-label indications treatment is increasing. General off-label indications treated with subcutaneous and intravenous immunoglobulins include multifocal motor neuropathy, Guillain Barre Syndrome, stiff person syndrome and dermatomyositis.
The ongoing COVID-19 pandemic will in addition leverage the industry, as healthcare providers are thoroughly researching on the application of immunoglobulins in the COVID-19treatment., according to the Fact.MR study.
Huge Potential in Immunology
Neurology remain the prominent category in the immunoglobulins market. The segment is anticipated to account for two-fifth of the overall share.
“Growing prevalence of neurological disorders such as Multifocal Motor Neuropathy and Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)are projected to leverage the segment’s expansion.”, says Fact.MR.
Future Immunoglobulins demand will be heavily influenced by broader application in immunology. The immunology industry is expected to be the second biggest market share account for 35% of the overall market share all through the assessment period. Intramuscular, subcutaneous and intravenous immunoglobulins are effective for the rare disorders treatment in the immunology and neurology disease segments, thus the growing market share. Growing number patients experiencing disorders such as Guillain Barre Syndrome, primary humoral immunodeficiency and multifocal motor neuropathy are also rising.
Request Custom report to get specific research solutions: https://www.factmr.com/connectus/sample?flag=RC&rep_id=4788
Immunoglobulins Industry will see Growth Prospects in US
US is poised to remain the key player of the global immunoglobulins market over the assessment period. The region is expected to expand robustly at a CAGR of about 7.5% in 2021 and accounting for a market share of over two-fifth through 2026. According to the study, growth in the region is ascribed to the higher prevalence of immunological, neurological and other disorders, higher implementation of IVIG products and noteworthy reimbursement coverage together with existence of key market players.
The study further states that the China and India growing at a CAGR of around 8.9% and accounting for over a quarter of the overall market. Growing healthcare market, acceptance of immunoglobulins products, and untapped potential in emerging nations and growing geriatric populace are the key drivers boosting expansion of the Asia-Pacific market.
Molecular Immunoglobulins Indications & Following Pipeline Products Development Top 2 Focus Areas: Fact.MR Survey
Immunoglobulins market remains highly consolidated, with the leading three players capturing overall three-fifths of the total market share. Fact.MR’s survey with thought leaders disclosed that molecular immunoglobulins indications and subsequent development of pipeline products are likely to be a key strategy for market player in 2021 and beyond. The modified edition of the report offers a comprehensive coverage of the likely key strategies of market players. Some of the players profiled in the report are CSL Behring, Shire, Kedrion Biopharma Inc., Octapharma, Grifols, S.A., China Biologic Products Holdings, Inc., Sanquin Biotest AG, and LFB SA. The updated edition also offers a detailed analysis on the COVID-19 impact on this market.
Request a report sample to gain comprehensive market insights at: https://www.factmr.com/checkout/4788/S
Market research and consulting agency with a difference! That’s why 80% of Fortune 1,000 companies trust us for making their most critical decisions. While our experienced consultants employ the latest technologies to extract hard-to-find insights, we believe our USP is the trust clients have on our expertise. Spanning a wide range – from automotive & industry 4.0 to healthcare & retail, our coverage is expansive, but we ensure even the most niche categories are analyzed. We are headquartered in Dubai, and operate from our sales office in Dublin, Ireland. Reach out to us with your goals, and we’ll be an able research partner.
Unit No: AU-01-H Gold Tower (AU), Plot No: JLT-PH1-I3A,
Jumeirah Lakes Towers, Dubai,
United Arab Emirates
MARKET ACCESS DMCC Initiative